LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion for First-Line Maintenance Treatment in BRCA-Mutated Advanced Ovarian Cancer - BioSpace

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion for First-Line Maintenance Treatment in BRCA-Mutated Advanced Ovarian Cancer  BioSpace

AstraZeneca and Merck's LYNPARZA Is the Only PARP Inhibitor in This Setting to Demonstrate an Improvement in Progression-Free Survival for Patients Who ...



Comments

Popular posts from this blog

“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more

“Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study - The Lancet” plus 4 more

“Ground glass opacity: Causes, symptoms, and treatments - Medical News Today” plus 1 more